NuvOx Pharma

NuvOx Pharma is developing a nanotechnology DDFPe for oxygen delivery. NuvOx Pharma is creating a drug platform that, after intravenous injection, travels through the blood to first reach the lungs for oxygen absorption and eventually arrives at hypoxic tissues, where it passively delivers oxygen. Indications for NuvOx’s drugs include stroke (Phase II preparation), oncology (Phase II preparation), and sickle cell crisis (Phase Ib preparation).